BlackRock Inc. boosted its holdings in shares of Scholar Rock Holding Corp (NASDAQ:SRRK) by 9.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 903,095 shares of the company’s stock after purchasing an additional 76,755 shares during the period. BlackRock Inc. owned approximately 3.44% of Scholar Rock worth $14,323,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Monashee Investment Management LLC purchased a new position in Scholar Rock during the 2nd quarter worth $1,269,000. TD Asset Management Inc. grew its position in Scholar Rock by 16.9% during the 2nd quarter. TD Asset Management Inc. now owns 22,415 shares of the company’s stock worth $356,000 after purchasing an additional 3,236 shares during the last quarter. Swiss National Bank purchased a new position in Scholar Rock during the 2nd quarter worth $560,000. Alps Advisors Inc. purchased a new position in Scholar Rock during the 2nd quarter worth $870,000. Finally, Northern Trust Corp grew its position in Scholar Rock by 10.8% during the 2nd quarter. Northern Trust Corp now owns 172,354 shares of the company’s stock worth $2,734,000 after purchasing an additional 16,853 shares during the last quarter. 58.52% of the stock is currently owned by institutional investors.
Several brokerages have issued reports on SRRK. Zacks Investment Research downgraded shares of Scholar Rock from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine raised shares of Scholar Rock from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Wednesday, August 14th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.07). The firm had revenue of $5.04 million for the quarter, compared to analyst estimates of $5.38 million. On average, research analysts forecast that Scholar Rock Holding Corp will post -1.7 EPS for the current year.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Featured Story: How to trade on quiet period expirations
Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Corp (NASDAQ:SRRK).
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.